Pulse Biosciences, Inc. (PLSE) is a Medical - Instruments & Supplies company in the Healthcare sector, currently trading at $20.12. It has a SharesGrow Score of 44/100, indicating a mixed investment profile with 3 out of 7 criteria passed.
Analyst consensus target is PLSE = $30 (+49.1% upside).
Valuation: PLSE trades at a trailing Price-to-Earnings (P/E) of -17.1 (S&P 500 average ~25).
Financials: revenue is $350,000, -100%/yr average growth. Net income is $73M (loss), growing at -11.5%/yr. Net profit margin is -20794.6% (negative). Gross margin is -360% (+1246.3 pp trend).
Balance sheet: total debt is $8M against $81M equity (Debt-to-Equity (D/E) ratio 0.09, conservative). Current ratio is 10.53 (strong liquidity). Debt-to-assets is 7.8%. Total assets: $96M.
Analyst outlook: 2 / 4 analysts rate PLSE as buy (50%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 90/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 27/100 (Fail), Future 64/100 (Pass), Income 10/100 (Fail).
